Methods which focus on correction of the endogenous ABCD1 gene in vivo such as homology-independent targeted integration (HITI) [16] or treatment with a direct intracerebral injection of lentiviral ABCD1 [17] may become a treatment paradigm for X-ALD patients in the future. Here, ABCD1 is linked to X-linked adrenoleukodystrophy.